key: cord-0977475-x0ko9luu
authors: Odeyemi, Yewande E.; Chalmers, Sarah J.; Barreto, Erin F.; Jentzer, Jacob C.; Gajic, Ognjen; Yadav, Hemang
title: Early, biomarker-guided steroid dosing in COVID-19 Pneumonia: a pilot randomized controlled trial
date: 2022-01-04
journal: Crit Care
DOI: 10.1186/s13054-021-03873-2
sha: 02ef81e05ad974883980ed3809cc316883c92b11
doc_id: 977475
cord_uid: x0ko9luu

ClinicalTrials.gov identifier (NCT number): NCT03852537, Registered February 25, 2019.

Although corticosteroid administration has been associated with improved outcomes in severe COVID-19 pneumonia, their ideal use remains undefined with a "one size fits all" approach used, irrespective of the individual inflammatory response [1] . Recent studies have highlighted distinct COVID-19 inflammatory phenotypes with differential responses to corticosteroids [2] . Our goal was to assess the feasibility and safety of an individualized, biomarker-guided corticosteroid dosing approach utilizing C-reactive protein (CRP) in patients with pneumonia and acute hypoxemic respiratory failure (AHRF). With the COVID-19 outbreak, a separate COVID-19 trial arm was created, which we report here.

This was a single-center, pilot randomized controlled trial conducted in Mayo Clinic, Rochester, Minnesota from March 2020 through November 2020. Patients with COVID-19 pneumonia and AHRF were randomized to biomarker-guided corticosteroid dosing versus usual care. In the intervention arm, corticosteroid dosing and duration was adjusted to daily CRP level. The dosing algorithm was extrapolated from prior retrospective data [3] . Corticosteroid use and dosing in the usual care arm was determined by the treating physician. Of note, there was a practice change related to corticosteroid administration during the enrollment period following the publication of the RECOVERY trial [4] . All patients had CRP and Troponin measurements on the day of enrollment and then daily for 5 days. The primary outcome was the feasibility of the trial protocol. Secondary outcomes included cumulative corticosteroid exposure, hospitalfree days, oxygen-free days, and evidence of cardiac injury (troponin elevation, echocardiographic evidence of new cardiac dysfunction).

Of 41 patients enrolled, 19 were randomized to the intervention arm and 22 to the usual care arm. No significant differences were observed between groups with regards to age, sex, comorbidities, and oxygen delivery devices (see Table 1 ). Study treatment protocol was followed in 18 (95%) patients in the intervention arm. In the intention to treat analysis the intervention arm had more oxygen-free days (23.5 (21, 25) versus 21 (17, 25), p = 0.033) and hospital-free days (21 (18, 22) versus 18.5 (15, 21), p = 0.05) than the usual care arm. Daily distribution of CRP in both arms revealed significantly lower CRP levels on day 3 in the intervention arm compared to the usual care arm (see Fig. 1 ).

Seventeen (90%) patients in the intervention arm received corticosteroids and 2 patients (due to low CRP levels) did not base on the CRP guided protocol. 11 The results of this single-center pilot randomized controlled clinical trial show that an individualized biomarker-guided corticosteroid dosing approach in pneumonia using CRP is feasible and safe with high adherence to the study protocol. Although not powered to detect differences in patient-centered outcomes, the individualized CRP-guided corticosteroid dosing approach was associated with increased oxygen-free days, hospital-free days, and a lower corticosteroid cumulative exposure in the intervention arm. This is the first study evaluating an individualized biomarker-guided strategy to inform corticosteroid dosing in COVID-19 pneumonia. The protocol outlined can provide a more precise strategy of adjunct drug delivery than the current one-size-fits-all approach. A larger, multicenter clinical trial is needed to determine the efficacy and safety of this approach. COPD, n (%) 0 (0%) 0 (0%)

Admitted to ICU at randomization, n (%) 10 (45%) 4 (21%)

Sepsis, n (%) 0 (0%) 0 (0%) Diabetes, n (%) 5 (23%) 4 (21%)

Asthma, n (%) 4 (18%) 1 (5%)

Home oxygen use, n (%) 0 (0%) 0 (0%) Dementia, n (%) 0 (0%) 1 (5%) 

COVID-19) Treatment Guidelines. National Institutes of Health

Latent class analysis reveals COVID-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids

Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial

Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

• fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types 

Not applicable.

The authors declare that they have no competing interests.